

<b>Notice of Allowability</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/675,201	TAGAMI ET AL.	
	Examiner	Art Unit	
	Dawn Garrett	1774	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to the after final amendment dated February 27, 2004.

2.  The allowed claim(s) is/are 18-20.

3.  The drawings filed on 19 September 2002 are accepted by the Examiner.

4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)  All    b)  Some\*    c)  None    of the:

1.  Certified copies of the priority documents have been received.

2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.

3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5.  A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

6.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.

(a)  including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached

1)  hereto or 2)  to Paper No./Mail Date \_\_\_\_\_.

(b)  including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

7.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

#### Attachment(s)

1. <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	6. <input checked="" type="checkbox"/> Interview Summary (PTO-413), Paper No./Mail Date <u>20040402</u> .
3. <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date _____	7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment
4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance
	9. <input type="checkbox"/> Other _____.

#### **EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

2. Authorization for this examiner's amendment was given in a telephone interview with Harris Pitlick on April 2, 2004.

3. The application has been amended as follows:





In claim 18, bottom of page 2 to top of page 3, the following was deleted “**with the premise that the combination of substituted group X<sup>13</sup> and X<sup>14</sup>, X<sup>3</sup> and X<sup>4</sup>, X<sup>10</sup> and X<sup>11</sup>, and X<sup>6</sup> and X<sup>7</sup> with any ring structure in the general formula (3) is omitted:**”





In claim 19, bottom of the page, the following was deleted “**with the premise that the combination of substituted group X<sup>13</sup> and X<sup>14</sup>, X<sup>3</sup> and X<sup>4</sup>, X<sup>10</sup> and X<sup>11</sup>, and X<sup>6</sup> and X<sup>7</sup> with any ring structure in the general formula (3) is omitted:**”

In claim 19, twelfth line under the structural formula, “**comprises an amine group or an alkenyl group**” was deleted and **- -comprises an amine group - -** was inserted.



In claim 20, "The compound according to Claim 19, wherein the compound has at least one structure selected from the group consisting of formulae (A-1) through (A-28), (B-1), (B-2), (B-9) and (B-13) through (B-19) as described in the specification." was deleted and the following was inserted:

-- A compound selected from compounds represented by the following formulae:








(A-6)




(A-7)





(A-8)







(A-9)





(A-10)








(A-14)




(A-15)




(A-16)





(A-17)









(A-18)





(A-19)













(A - 2 3)





(A - 2 4)






Art Unit: 1774


(A - 27)




(A - 28)

( $\phi$  is phenyl group)


(B - 1)




(B - 2)





(B-9)





(B-13)





(B-14)




(B-15)





(B-16)




(B-17)



(B-18)



(B - 19)



## **REASONS FOR ALLOWANCE**

4. The following is an examiner's statement of reasons for allowance:

The closest prior art is considered to be Chemistry Letters (2), pages 157-158, (1996), which teaches a compound with the skeleton of compound (3) per claim 19, but requires an alkenyl group substituted with halogen atoms (see R group number 7, first column, page 157). Claim 19 requires a compound (3) to have at least one amine group, which is not taught or rendered obvious by the article. In addition, the compounds disclosed in the article do not teach or render obvious any of the formulas of claim 20. Furthermore, the article fails to teach or to render obvious the disclosed compounds have luminescent properties or that they may be luminescent materials in an organic electroluminescent device. Claims 18-20 are allowed.

5. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

## **TERMINAL DISCLAIMER**

6. The terminal disclaimer filed on February 27, 2004 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of U.S. Serial No. 10/244,164 has been reviewed and is accepted. The terminal disclaimer has been recorded.

## CONCLUSION

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dawn Garrett whose telephone number is 571-272-1523. The examiner can normally be reached Monday through Friday during normal business hours. Please allow the examiner twenty-four hours to return your call.

If reasonable attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cynthia Kelly, can be reached at 571-272-1526. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

*Dawn Garrett*  
DAWN GARRETT  
EXAMINER  
ART UNIT 1774

D.G.  
April 2, 2004